Vivos Inc. (RDGL)

Executive Summary / Key Takeaways

• Differentiated Technology with Dual Market Potential: Vivos Inc. (RDGL) is pioneering precision radionuclide therapy with its yttrium-90 (Y-90) based RadioGel, an injectable particle-gel designed for non-resectable tumors in both animals (IsoPet) and humans. This technology offers highly localized radiation delivery with minimal collateral tissue damage, a significant differentiator in oncology.
• Strategic Regulatory Momentum: RadioGel received FDA Breakthrough Device designation in December 2023, accelerating its path for human clinical trials. The company is actively pursuing an Investigational Device Exemption (IDE) application in Q3 2025, a critical step towards unlocking the substantial human oncology market.
• Growing Animal Therapy Traction: The IsoPet animal therapy division achieved record growth in Q1 2025, with a 150% year-over-year increase in treatment volume. New revenue streams from clinic certification and product sales are emerging, with a target to reach breakeven status for this division in 2026.
• Significant Capital Requirements and Going Concern Risk: Despite recent capital raises and revenue growth, Vivos Inc. operates with recurring losses and an insufficient cash position, leading to a "going concern" qualification from its auditors. The company requires approximately $3 million annually for operations and an additional $9 million over the next 36 months for its strategic initiatives, necessitating further financing.
• Expanding IP and Future Horizons: Vivos is actively diversifying its intellectual property, exploring other isotopes (P-32, Lu-177, Ac-225) for new indications, and leveraging its hydrogel technology (PrecisionGel) for broader applications, including a new distribution agreement with Akina, Inc.

The Genesis of Precision: Vivos Inc.'s Vision in Radiation Oncology

Vivos Inc. (RDGL) stands at the forefront of radiation oncology, dedicated to revolutionizing cancer treatment through its innovative yttrium-90 (Y-90) based precision radionuclide therapy. Incorporated in 1994, the company's overarching vision is to globally empower physicians, medical researchers, and patients with new isotope technologies that offer safe and effective treatments for cancer. This mission is embodied in its flagship product, RadioGel, and its veterinary counterpart, IsoPet.

The company's journey began with a pivotal moment in 2013 when the U.S. Food and Drug Administration (FDA) classified RadioGel as a device for human therapy for non-resectable cancers. This classification is a strategic advantage, potentially offering a faster regulatory pathway compared to drug approvals. In the highly competitive medical device industry, where giants like Elekta AB (EKTA-B), Siemens Healthineers AG (SMMNY), and Accuray Incorporated (ARAY) dominate with comprehensive radiation therapy systems, Vivos carves out a specialized niche. While larger players offer broad solutions, Vivos focuses on a targeted, injectable approach that could offer distinct advantages in specific clinical scenarios.

Technological Edge: The Power of Localized Radiation

Vivos Inc.'s core competitive advantage lies in its proprietary RadioGel technology, a sophisticated injectable particle-gel for Precision Radionuclide Therapy. This innovative system is designed to deliver a potent, localized radiation dose directly to cancerous tumors, minimizing impact on surrounding healthy tissue. The hydrogel, which is liquid at room temperature, gels upon reaching body temperature after injection, effectively locking in tiny Y-90 phosphate particles, each less than two microns in size.

The Y-90 isotope emits beta radiation, consisting of high-speed electrons that travel only a short distance. This characteristic allows for a very high local radiation dose directly within the tumor, a tangible benefit over external beam radiation or systemic therapies. The short half-life of Y-90 (2.7 days) means radioactivity drops to 5% of its original value after just ten days, enabling patients to potentially return home immediately post-treatment without significant risk of radiation exposure to family members. This operational benefit could translate into improved patient quality of life and reduced healthcare costs.

Vivos is not resting on its laurels; its R&D initiatives are actively expanding the technological moat. In December 2024, a strategic meeting confirmed Y-90's effectiveness for current targeted indications while also deciding to explore alternative isotopes. P-32, with its longer half-life, could offer advantages for international shipments. Lu-177, a lower-energy isotope with reduced penetration, might be beneficial for therapies near critical structures, potentially yielding a higher therapeutic ratio. Ac-225, an alpha emitter with extremely low penetration, holds promise for treating brain tumors due to its homogeneous distribution within the hydrogel. The company has already secured trademarks like BetaGel and AlphaGel for these future applications, with laboratory, animal, and human studies in India planned over the next two years. This multi-isotope strategy aims to broaden the addressable market and enhance treatment specificity, strengthening Vivos' long-term competitive position.

Beyond direct cancer treatment, Vivos is leveraging its hydrogel technology for other applications under the "PrecisionGel" trademark. A new provisional patent filed in January 2025 covers the retention, transport, and release of a broad range of agents, including radioactive and non-radioactive materials, particles, molecules, cells, and viruses. This diversification strategy could generate additional income streams, as evidenced by the Q2 2025 contract with Akina, Inc. for hydrogel distribution.

Dual Market Strategy: IsoPet's Growth and RadioGel's Breakthrough Path

Vivos Inc. pursues a dual-market strategy, addressing both veterinary and human oncology. Its IsoPet Solutions division, established in May 2016, targets the veterinary market. In January 2018, the FDA classified RadioGel as a device for animal therapy, specifically for feline and canine sarcomas, with the potential for broader application to most solid tumors in animals without additional regulatory approvals. This regulatory clarity allowed Vivos to launch IsoPet commercially in July 2019, marking its first commercial sale.

The animal therapy segment is demonstrating promising growth. Q1 2025 saw a record-breaking performance, with a 150% year-over-year increase in treatment volume. This growth is supported by expanding marketing efforts, including website communication, social media, conferences, and journal publications, aimed at increasing certified clinics and patient numbers. The company has also begun billing clinics for certification in 2025, a new revenue stream, and implemented volume pricing to stimulate interest. Management is targeting breakeven status for the Animal Therapy Division in 2026, a significant operational milestone. The University of Florida Veterinary Hospital's recent certification underscores the growing adoption of IsoPet.

For human therapy, the path is more rigorous but equally promising. In 2021, Vivos strategically modified RadioGel's indication for use to focus on specific thyroid carcinomas, a move designed by its Medical Advisory Board to provide a more efficient pathway to regulatory clearance. A major catalyst occurred in December 2023 when RadioGel received the FDA's Breakthrough Device designation. This designation grants Vivos access to a rapid review process for Investigational Device Exemption (IDE) comments, which the company has been actively utilizing in Q1 and Q2 2025. Vivos intends to submit its FDA IDE application in Q3 2025, leveraging both animal and human therapy safety and efficacy data.

Beyond the U.S., Vivos is pursuing an expanded permit from the DCGI to conduct human clinical trials for commercial applications in India, establishing a Limited Liability Company there. This international expansion could provide a cost-effective production site and accelerate market penetration. The long-term plan involves expanding indications for use in phases: initially for lymph nodes associated with thyroid cancer, then cancerous lung nodules, and ultimately all non-resectable solid tumors.

Financial Performance and Liquidity: A High-Stakes Development Phase

Vivos Inc.'s financial performance reflects its early-stage development and significant investment in R&D and regulatory pathways. For the six months ended June 30, 2025, the company reported net revenues of $41,748, a substantial increase from $18,000 in the prior-year period, representing 131.9% growth. This growth was driven by IsoPet therapies, product sales, freight, and approximately $20,000 from new clinic licensing and certification revenues. However, the cost of goods sold surged to $85,583 from $16,780, resulting in a gross loss of $43,835, significantly wider than the $1,220 gross loss in the comparable period. This increase in COGS is attributed to the company's strategy of ordering hydrogel to increase treatment capacity, building up inventory.

Operating expenses for the six months ended June 30, 2025, totaled $1.49 million, up from $1.10 million in the prior year. This increase was primarily due to higher professional fees ($946,723 vs. $683,452), driven by consultants and vested Restricted Stock Units, increased general and administrative expenses ($133,117 vs. $78,345), and a ramp-up in research and development activities ($227,246 vs. $157,109) in both India and the U.S. Consequently, the net loss for the six months ended June 30, 2025, widened to $1.48 million from $1.06 million.

As of June 30, 2025, Vivos held $2.66 million in cash and had working capital of $2.68 million. While net cash provided by financing activities for the six months was $1.51 million, net cash used in operating activities was $1.06 million.

The company's independent registered public accounting firm has expressed substantial doubt about Vivos Inc.'s ability to continue as a going concern, citing recurring losses, limited revenue, and an accumulated deficit. Management explicitly states that current cash levels are insufficient to cover fixed and variable obligations.

Vivos requires approximately $3 million annually to maintain current operating activities. Over the next 36 months, the company estimates needing an additional $9 million to fund the FDA approval process for human clinical trials, conduct Phase I and pilot clinical trials, activate regional IsoPet clinics, establish an independent production center, and initiate international regulatory approvals. The ability to secure this capital through strategic transactions or further Regulation A Offerings is paramount; failure to do so would necessitate delaying business strategy and could jeopardize operations.

Competitive Landscape and Strategic Positioning

Vivos Inc. operates in a highly specialized segment of the radiation oncology market, positioning itself as a niche innovator rather than a broad-spectrum provider like industry giants. Compared to Elekta, which offers comprehensive radiation therapy and oncology solutions, or Siemens Healthineers, with its advanced imaging-guided systems, Vivos' injectable RadioGel/IsoPet technology offers a distinct value proposition. Its direct tumor injection method potentially provides greater accessibility and lower upfront deployment costs for specific applications, particularly in veterinary oncology or underserved human markets.

While larger competitors benefit from economies of scale, established global footprints, and faster innovation cycles in integrated software-hardware ecosystems, Vivos' strength lies in its targeted, cost-effective brachytherapy solution. Accuray Incorporated, another player in radiation therapy systems, focuses on robotic precision. Vivos' approach, emphasizing proprietary isotope-based solutions, could offer an edge in treatment specificity and a simpler, more affordable operating model for certain indications.

However, Vivos' smaller scale presents vulnerabilities. It likely faces higher customer acquisition costs and may lag in technological integration compared to the advanced diagnostic capabilities of Siemens. Financially, Vivos' current profitability margins and cash flow generation are significantly lower than those of its more mature, diversified competitors. For instance, RDGL's TTM Gross Profit Margin is -92.84%, starkly contrasting with Accuray's 0.32%. Similarly, RDGL's Operating Profit Margin of -5882.76% and Net Profit Margin of -6433.29% highlight the substantial operational losses compared to Accuray's positive operating profit margin of 0.02% and a net profit margin of -0.0035%. This indicates Vivos' intensive investment phase and limited revenue generation relative to its cost structure.

Vivos mitigates the risk of a single point of failure by negotiating for a second domestic production facility at Applied Process Engineering Laboratory (APEL), which will also focus on automated production development. This operational enhancement, coupled with expanding intellectual property and exploring international markets like India, demonstrates a strategic response to competitive pressures and a commitment to scaling its unique technology.

Risks and Outlook

The investment thesis for Vivos Inc. hinges on its ability to successfully commercialize its innovative precision radionuclide therapy. However, several critical risks loom. The most immediate is the "going concern" qualification, underscoring the urgent need for substantial additional capital. The timing and amount of future spending are highly dependent on the FDA's classification of RadioGel (Class II or Class III) and any requirements for additional clinical studies, which could significantly extend timelines and increase costs. Geopolitical events and capital market volatility also pose risks to financing efforts. Furthermore, the company's disclosure controls and procedures were deemed ineffective as of June 30, 2025, due to a material weakness related to proper segregation of duties, which requires remediation.

Despite these challenges, the outlook is cautiously optimistic, driven by the potential of its technology and strategic execution. The Breakthrough Device designation for RadioGel is a powerful accelerator for human trials. The targeted breakeven for the IsoPet animal therapy division in 2026 provides a tangible near-term goal and a potential source of future funding for human initiatives. The phased expansion of indications for use, coupled with the exploration of new isotopes and broader hydrogel applications, points to a robust long-term growth strategy. The successful establishment of international operations and a second domestic production facility would further de-risk and scale the business.

Conclusion

Vivos Inc. represents a high-potential, high-risk investment opportunity in the specialized field of radiation oncology. Its proprietary RadioGel technology, offering precise, localized Y-90 therapy for non-resectable tumors, presents a compelling technological differentiation against larger, more generalized competitors. The company's dual-market strategy, with the IsoPet animal therapy division showing early commercial traction and the RadioGel human therapy poised for accelerated regulatory review via Breakthrough Device designation, forms the core of its investment narrative.

The path forward, however, is critically dependent on securing the necessary capital to fund its ambitious R&D, clinical trials, and commercialization efforts. While the company's financial performance currently reflects significant losses and a going concern warning, the strategic initiatives, including IP expansion, isotope diversification, and operational scaling, are designed to build a sustainable, technologically advanced enterprise. Investors should closely monitor the progress of FDA approvals, capital raises, and the IsoPet division's journey towards profitability, as these will be key determinants of Vivos Inc.'s ability to translate its innovative technology into long-term shareholder value and establish itself as a leader in precision radionuclide therapy.